» Articles » PMID: 10224164

Evidence That Lipid Hydroperoxides Inhibit Plasma Lecithin:cholesterol Acyltransferase Activity

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 1999 May 1
PMID 10224164
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The oxidation of low density lipoproteins (LDL) has been implicated in the development of atherosclerosis. Recently, we found that polar lipids isolated from minimally oxidized LDL produced a dramatic inhibition of lecithin: cholesterol acyltransferase (LCAT) activity, suggesting that HDL-cholesterol transport may be impaired during early atherogenesis. In this study, we have identified molecular species of oxidized lipids that are potent inhibitors of LCAT activity. Treatment of LDL with soybean lipoxygenase generated small quantities of lipid hydroperoxides (20 +/- 4 nmol/mg LDL protein, n = 3); but when lipoxygenase-treated LDL (1 mg protein/ml) was recombined with the d > 1.063 g/ml fraction of human plasma, LCAT activity was rapidly inhibited (25 +/- 4 and 65 +/- 16% reductions by 1 and 3 h, respectively). As phospholipid hydroperoxides (PL-OOH) are the principal oxidation products associated with lipoxygenase-treated LDL, we directly tested whether PL-OOH inhibited plasma LCAT activity. Detailed dose-response curves revealed that as little as 0.2 and 1.0 mole % enrichment of plasma with PL-OOH produced 20 and 50% reductions in LCAT activity by 2 h, respectively. To gain insight into the mechanism of LCAT impairment, the enzyme's free cysteines (Cys31 and Cys184) and active site residues were "capped" with the reversible sulfhydryl compound, DTNB, during exposure to either minimally oxidized LDL or PL-OOH. Reversal of the DTNB "cap" after such exposures revealed that the enzyme was completely protected from both sources of peroxidized phospholipids. We, therefore, conclude that PL-OOH inhibited plasma LCAT activity by modifying the enzyme's free cysteine and/or catalytic residues. These studies are the first to suggest that PL-OOH may accelerate the atherogenic process by impairing LCAT activity.

Citing Articles

Association of interleukin-2, interleukin-21 and interleukin-23 with hyperlipidemia in pediatric type 1 diabetes.

Khalil R, Abdel-Moneim A, Yousef A, Abdel-Rahman H, Zanaty M, El-Sayed A Mol Biol Rep. 2021; 48(7):5421-5433.

PMID: 34328597 DOI: 10.1007/s11033-021-06545-0.


ApoE and apoC-III-defined HDL subtypes: a descriptive study of their lecithin cholesterol acyl transferase and cholesteryl ester transfer protein content and activity.

Amaya-Montoya M, Pinzon-Cortes J, Silva-Bermudez L, Ruiz-Manco D, Perez-Matos M, Jimenez-Mora M Lipids Health Dis. 2020; 19(1):106.

PMID: 32450892 PMC: 7249299. DOI: 10.1186/s12944-020-01291-x.


Paraoxonase 1 (PON1) Q192R genotypes and their interaction with smoking strongly increase atherogenicity and the Framingham risk score.

Souza-Nogueira A, Camargo A, Remondi F, Paoliello M, Richter R, Furlong C Arch Endocrinol Metab. 2016; 60(5):426-435.

PMID: 27812605 PMC: 10118632. DOI: 10.1590/2359-3997000000184.


Urinary oxidative stress markers in children with autism.

Damodaran L, Arumugam G Redox Rep. 2011; 16(5):216-22.

PMID: 22005342 PMC: 6837661. DOI: 10.1179/1351000211Y.0000000012.


Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein.

Shao B, Oda M, Oram J, Heinecke J Chem Res Toxicol. 2010; 23(3):447-54.

PMID: 20043647 PMC: 2838938. DOI: 10.1021/tx9003775.